Biophytis - Convening of Another Combined General Meeting at a Later Date
Paris, France, Cambridge (Massachusetts, United States), April 27, 2021, 8AM
CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company focused on the development of therapeutics aimed at
slowing the degenerative processes associated with aging and improving
functional outcomes for patients suffering from age-related diseases, including
severe respiratory failure in patients suffering from COVID-19, informs its
shareholders that the combined Annual General Meeting (AGM) held on April 26,
2021 was unable to deliberate, as the required quorum was not reached.
Biophytis' combined AGM took place today behind closed doors, due to the
COVID-19 pandemic. The shareholders taking part in the vote owned collectively
21 736 509 shares, or 19.11% of the share capital, and 19.46% of the voting
The 20% quorum necessary for holding an ordinary AGM on first call and the 25%
quorum necessary for holding an extraordinary General Meeting on first call
have not been reached. Therefore, in the absence of the quorum required to rule
on the ordinary and extraordinary resolutions, none of the proposed resolutions
as listed in the meeting notice published in the French official legal bulletin
Bulletin des Annonces Légales Obligatoires (BALO) n° 30, dated March 10,
2021, have been put to the vote of the shareholders and the AGM is adjourned.
Shareholders will therefore be invited to another combined AGM, on the second
call, to be held at a later date with the same agenda.
All of the documents regarding this combined AGM are available to shareholders
on the Company's website: www.biophytis.com, in the section Investors / General
If you are a Biophytis shareholder and wish to vote on the resolutions, you
* vote via the secured web portal VOTACCESS, this method is strongly
recommended in the current context of Covid-19,
* vote by post or proxy, in accordance with the terms and conditions indicated
in the Shareholders' letter and in the Bulletin des Annonces Légales
Obligatoires (BALO) n° 30, dated March 10, 2021, available on Biophytis'
The vote of shareholders who submitted their vote via the post, email or the
Internet for the first general meeting remains valid and counted for the
general meeting on the second call.
Shareholders who did not vote by post, VOTACCESS or proxy as part of the first
combined General Meeting will be invited to vote by VOTACCESS or send their
forms and shareholder certificates after publication of the new meeting notice.
By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées
- 14, rue Rouget de L'Isle - 92862 ISSY-
LESMOULINEAUX Cedex 9, or via email: email@example.com
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, being developed as a treatment for sarcopenia in a Phase 2
clinical trial in the United States and Europe (SARA-INT). It is also being
studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of
severe respiratory manifestations of COVID-19 in Europe, Latin America, and the
US. A pediatric formulation of Sarconeos (BIO101) is being developed for the
treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris,
France, and Cambridge, Massachusetts.
The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS - ISIN:
US09076G1040). For more information visit www.biophytis.com
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. These forward-looking statements include statements regarding
Biophytis' anticipated timing for its Interim Analysis of Part 1 and release of
full study results. Such forward-looking statements are based on assumptions
that Biophytis considers to be reasonable. However, there can be no assurance
that the statements contained in such forward-looking statements will be
verified, which are subject to various risks and uncertainties including,
without limitation, delays in patient recruitment or retention, interruptions
in sourcing or supply chain, its ability to obtain the necessary regulatory
authorizations, COVID-19-related delays, and the impact of the current pandemic
on the Company's clinical trials. The forward-looking statements contained in
this press release are also subject to risks not yet known to Biophytis or not
currently considered material by Biophytis. Accordingly, there are or will be
important factors that could cause actual outcomes or results to differ
materially from those indicated in these statements. In France, please also
refer to the "Risk Factors" section of the Company's Annual 2019 Report and the
Company's Half Year 2020 Report available on BIOPHYTIS website
(www.biophytis.com). We undertake no obligation to publicly update or review
any forward- looking statement, whether as a result of new information, future
developments or otherwise, except as required by law.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
Life Sci Advisors
Sophie Baumont/Chris Maggos
T: +33 6 27 74 74 49